Boston Institute of Biotechnology

What Boston Institute of Biotechnology does

Boston Institute of Biotechnology (BIB) is a privately held, full-service Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in Southborough, Massachusetts, with US offices in Boston and San Francisco and primary manufacturing operations in Shanghai, China (Zhangjiang and Lingang). The company offers cGMP and non-GMP services spanning mammalian cell culture, microbial fermentation, gene therapy (AAV-focused), and cell therapy, serving pharmaceutical and biotechnology clients from preclinical through commercial stages across more than 160 completed projects and 130+ large molecule engagements.

BIB's technical platform rests on four proprietary, registered IP pillars: the Epic-CHO cell line (10 g/L mAb expression with doubled stability vs. leading international lines), the Grand-CHO Platform integrating cell line development, 3,000L N-1 perfusion, and 30,000L fed-batch production, Pulse Continuous Manufacturing (PCM) combining large upstream batches with continuous downstream processing, and the PanFlex-Engineering system enabling biopharmaceutical facility construction in approximately half the industry-standard time and cost. The company's physical asset base includes the world's first independently designed 30,000-liter stainless steel mammalian cell bioreactor (with 50,000L+ total volume), total facility capacity exceeding 200,000 liters, and a publicly announced plan to add 350,000+ liters of new fermentation capacity by December 2025. Quality systems are certified to FDA, EMA, PMDA, and China NMPA standards, enabling global regulatory submissions and IND/BLA support.

BIB operates a sales-led, enterprise GTM motion through a dedicated business development team (VP, Directors, and regional US/EU representatives) with quote-based engagement on every project. Revenue is generated through project-based contract manufacturing services, custom PanFlex facility-construction deals (exemplified by a $135M agreement with 89bio), and a Blue Whale Program offering risk-free manufacturing solutions. BIB functions as the US-based development and clinical manufacturing arm of a broader group that includes sister company BiBo Pharma, which operates large-scale commercial manufacturing; both entities share unified global leadership under Chairman & CEO Dr. Jiao Peng. The company claims a cost position of approximately $10 per gram of antibody versus industry norms of $100+/gram, supported by its ultra-large-scale bioreactors, Grand-CHO technology, and PCM efficiency gains of 50-300%.

Name

Boston Institute of Biotechnology

Legal name

Boston Institute of Biotechnology, LLC

Website

https://bostonbib.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Boston Institute of Biotechnology is a US-based, full-service CDMO offering cGMP mammalian, microbial, gene therapy, and cell therapy manufacturing services for biopharmaceutical clients from preclinical through commercial stages, anchored by the world's first 30,000L bioreactor and the Grand-CHO platform.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Contract manufacturing services
• Biopharmaceutical CDMO
• Cell line development
• Gene therapy manufacturing
• Biologics process development

Headquarters

HQ city

Southborough

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Full-spectrum CDMO services including cell line development, process development, GMP manufacturing, and quality control for biologics. Revenue generated through project-based contracts for drug substance and drug product manufacturing.
2. Engineering Services (PanFlex): PanFlex-Engineering system offered as a manufacturing solution to clients. Blue Whale Program provides financially risk-free manufacturing solutions with construction cost reduction of 50%.
3. Customized Production Line Construction: Engineering solutions for building client-specific production facilities. Example: $135M agreement with 89bio for dedicated production line construction at Lingang Base.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels9 records

Core offering

Boston Institute of Biotechnology (BIB) is a full-service Contract Development and Manufacturing Organization (CDMO) providing cGMP and non-cGMP services across mammalian cell culture, microbial fermentation, gene therapy, and cell therapy. The company offers end-to-end CMC capabilities—from cell line/strain development, process development and characterization, analytical and formulation development through to large-scale cGMP manufacturing at scales up to 30,000L—supported by proprietary technologies including the Grand-CHO platform, Epic-CHO cell line, Pulse Continuous Manufacturing, and PanFlex-Engineering facility construction system.

Product overview

Boston Institute of Biotechnology is a full-service CDMO (Contract Development and Manufacturing Organization) offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy services. The portfolio centers on eight core service products: Cell Line Development (using proprietary EPIC-2BOX platform with Epic-CHO cell lines), Gene Therapy (AAV-focused), Process Development, Analytical and Formulation Development, Process Characterization, Manufacturing & Support, GMP Capacity, and PanFlex-Engineering Facility Construction. These services are unified by the Grand-CHO Platform—an integrated 'Three-in-One' approach combining cell line development, process optimization, and manufacturing technology. Key enabling technologies include Pulse Continuous Manufacturing (PCM) for high-efficiency production and the PanFlex-Engineering system for rapid facility construction. The Blue Whale Program provides risk-free manufacturing solutions. The company operates world-leading 30,000L ultra-large bioreactors and maintains facilities in the USA and China, targeting a unified platform for biologics development from preclinical through commercial production.

Differentiator

Problem solved

Functional benefit

Brands

• PanFlex-Engineering: Proprietary engineering system enabling construction of biopharmaceutical production sites in half the time and cost of comparable developments.
• Grand-CHO Platform
• Epic-CHO Cell Line
• Blue Whale Program
• Pulse Continuous Manufacturing (PCM)

Products and services

• Cell Line Development Comprehensive mammalian cell line and microbial strain development service that delivers high-yield cell lines (up to 10 g/L for monoclonal antibodies) using GS/DHFR expression systems with stability guarantees; designed for biopharmaceutical companies needing production-ready cell substrates.
• Gene Therapy Services Full-spectrum AAV-focused gene therapy CDMO services including vector design, production, purification, and analytical characterization; positioned as the first gene therapy CMC service provider globally serving multinational pharmaceutical companies.
• Process Development End-to-end upstream, downstream, and formulation process development for recombinant proteins, viral vaccines, and gene therapies using microbial or cell cultures; emphasizes QbD and DoE methodologies to deliver reproducible, robust, scalable, manufacturing-friendly processes.
• Analytical and Formulation Development Comprehensive analytical and formulation development services including analytical method development and optimization, assay qualification/transfer, forced degradation studies, structure elucidation, ICH stability studies, bioassays, potency assays, mass spectrometry, and LC/MS; supports biologics programs from preclinical through commercial.
• Process Characterization FDA-recommended QbD-driven process characterization studies that establish Critical Process Parameters (CPPs) and Proven Acceptable Ranges (PARs) using Design of Experiments (DoE) and 1L parallel scale-down modeling; reduces time and cost by 30-50% versus traditional methods.
• Manufacturing and Support Ultra-large-scale cGMP commercial production up to 50,000L for drug substance, along with drug product fill-finish including vials, liquid, and lyophilization; delivers tox and cGMP manufacturing for late-stage and commercial biopharmaceutical products.
• GMP Capacity cGMP manufacturing services across microbial (50L-50,000L), mammalian (200L-50,000L), gene therapy (200L-2,000L), and pDNA (50L-500L) platforms with facilities in the USA and China; reports 99% client satisfaction and 95% on-time completion rate.
• PanFlex-Engineering Facility Construction (Blue Whale Program) Proprietary PanFlex-Engineering system that delivers biopharmaceutical production-site construction in approximately half the time and cost of comparable developments, bundled under the financially risk-free Blue Whale Program where fees are refundable regardless of commercial outcome.

Quantifiable outcome

• Antibody production cost reduced from hundreds of dollars to $10 per gram
• +7 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered major and core.

• 89biomajorOthers · 1 April 202489bio (holder of Pegozafermin for metabolic dysfunction-associated steatohepatitis/MASH) partnered with BiBo Pharma to build a dedicated production line at Lingang Base to support commercialization. Under the agreement, 89bio will pay an aggregate of $135 million toward construction of the production facility.
• BiBo PharmacoreStrategic or Co-development PartnerBiBo Pharma is BIB's sister company operating under the same global management team. BIB and BiBo Pharma collaborate on a global scale, leveraging shared resources and expertise. BiBo Pharma focuses on large-scale commercial manufacturing while BIB provides development and GMP services. The companies share PanFlex-Engineering technology and operate integrated facilities in Shanghai, China.

Scale indicators15 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• WuXi Biologics: Largest China-based biologics CDMO offering end-to-end discovery, development, and GMP manufacturing services for mAbs, bispecifics, and recombinant proteins. Direct competitor to BIB/BiBo in mammalian cell culture CDMO services, particularly for global biopharma clients seeking Asian manufacturing capacity.
• Samsung Biologics: Korean CDMO operating some of the world's largest single-site mammalian cell culture capacity and offering commercial-scale biologics manufacturing. Comparable to BIB in serving large-scale, late-stage commercial biologics programs, though with a more established global customer base.
• AGC Biologics: Global CDMO providing mammalian and microbial biologics manufacturing, gene therapy, and vaccine services across facilities in the US, Europe, and Asia. Closely comparable to BIB in service scope — particularly gene therapy CDMO — though with smaller average bioreactor scale.
• GenScript ProBio: CDMO division of GenScript offering cell line development, plasmid/mRNA production, viral vectors, and biologics manufacturing. Overlaps with BIB in cell line development services (CHO-based expression) and gene therapy CDMO offerings.
• Rentschler Biologics: European-based CDMO specializing in mammalian cell culture-derived biologics manufacturing from clinical to commercial scale. Comparable to BIB in modality focus (mAbs/recombinant proteins) and integrated CMC service offering.
• Cytovance Biologics: US-based CDMO offering mammalian and microbial biologics process development and GMP manufacturing. Comparable to BIB in serving smaller-to-mid biopharma clients with mammalian and microbial expression systems, though at smaller scale.

Broad incumbents

• Lonza: Global leader in contract biologics manufacturing with extensive mammalian and microbial capacity across multiple continents. Direct service-line competitor in biologics CDMO, but operates at materially larger scale with deeper regulatory history and broader service portfolio.
• Boehringer Ingelheim BioXcellence: Biopharmaceutical contract manufacturing business of Boehringer Ingelheim offering large-scale mammalian cell culture and microbial fermentation services. Comparable as a full-service biologics CDMO, anchored by the Biberach facility's commercial-scale mammalian capacity.
• Catalent: Large global CDMO offering biologics, cell and gene therapy, and fill-finish services across multiple sites. Overlaps with BIB in biologics manufacturing and gene therapy CDMO but operates a much broader and more diversified service portfolio.
• Thermo Fisher Scientific (Patheon): Global CDMO (via Patheon) including biologics manufacturing services at sites such as St. Louis and Greenville. Comparable as a broad biopharma services incumbent with commercial-scale mammalian capacity, though biologics is one segment of a much larger services franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bostonbib
• YouTubeyoutube.com/channel/UCGiDf2pKqSK2lDcecvyQFZg
• Facebookfacebook.com/bostonbib
• LinkedInlinkedin.com/company/boston-institute-of-biotechnology-llc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Institute of Biotechnology